Actively Recruiting
Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer
Led by Hebei Medical University Fourth Hospital · Updated on 2025-05-29
60
Participants Needed
1
Research Sites
363 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a single-center, single-arm, prospective clinical trial designed to evaluate the efficacy of local excision followed by postoperative chemoradiotherapy in patients with early-stage low/ultra-low rectal cancer. The study plans to enroll 60 patients with T1-2N0M0 low/ultra-low rectal cancer.
CONDITIONS
Official Title
Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- ECOG performance status 0-1
- Biopsy-proven rectal adenocarcinoma
- Primary tumor located 8 cm or less from the anal verge
- Clinical stage I rectal cancer (cT1-2N0M0)
- Strong preference to preserve the anus and refusal of abdominoperineal resection
- Surgeon confirms that local resection is feasible
- No contraindications to chemoradiotherapy
You will not qualify if you...
- Not meeting all inclusion criteria
- Refusal to sign informed consent
- Impaired cognitive function or psychiatric disorders
- Deemed ineligible by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Actively Recruiting
Research Team
C
chaoxi Zhou
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here